VivaVision Biotech, Inc   Report issue

For profit Phase 2
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2020
NCT04556838
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

VivaVision | VivaVision Biotech, Inc

Active Ingredients

Drugs in Phase 2 Trials (3)

vvn001 (1 trial)

vvn461 (1 trial)

vvn539 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3